Yahoo! Sports

’The Line Gets Blurred in a Negative Way’ — Draymond Green Questions Stephen A. Smith’s ’Journalist’ Label for 1 Key Reason

ESPN’s Stephen A. Smith has always drawn eyeballs to him thanks to his outspoken, energetic, and excitable personality. He is known for his hot takes and provides entertainment value to millions of ...

Can picking personal Lotto lines change the odds of winning? We ran the numbers

An analysis of Lotto entries shows many players gravitate to the same number combinations, increasing prize sharing and ...
Daily Record

Children used as drugs couriers by 'county lines' gangs in record numbers

The numbers of children being ruthlessly exploited by 'county lines' drugs gangs are at record levels, the Daily Record can reveal. County lines operate where criminals from major cities have expanded ...
Monthly Prescribing Reference

First-Line Trodelvy Regimens Approved for Triple-Negative Breast Cancer

Credit: Gilead Trodelvy is now FDA-approved for first-line treatment of advanced TNBC, significantly improving PFS in phase 3 trials. Trodelvy-based regimens significantly improved PFS over standard ...
Pharm Exec

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.
Healio

Trodelvy earns FDA approval as first-line treatment for triple-negative breast cancer

Please provide your email address to receive an email when new articles are posted on . Sacituzumab govitecan-hziy is approved for adults with triple-negative breast cancer across PD-L1 status. The ...
The American Journal of Managed Care

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

Regulatory labeling stratifies use by PD-L1 status: monotherapy for PD-L1–negative/checkpoint-ineligible disease and combination with pembrolizumab (or Qlex) for PD ...
Morningstar

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

– Approval Builds on Trodelvy’s Leadership in Second-Line mTNBC and Pre-Treated HR+/HER2- Metastatic Breast Cancer with More than 75,000 Patients Treated Globally – Gilead Sciences, Inc. (Nasdaq: GILD ...
Cure Today

FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer

Monotherapy in immunotherapy-ineligible patients improved median PFS to 9.7 vs 6.9 months versus physician’s-choice chemotherapy, with 50% vs 47% objective response rates. Combination therapy in PD-L1 ...
WebMD

HER2-Negative Breast Cancer

When you have breast cancer, one of the most important things to know is whether the cancer is at an early stage or if it has spread. Stage, type, size, and location of your tumor all can play a role ...
The American Journal of Managed Care

Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% lacking actionable PD-L1 eligibility and historically limited to ...